Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs

Bromfenac sodium Form I, characterized by a powder x-ray diffraction pattern in accordance with that shown in FIG. 1 and substantially free of any other physical forms of bromfenac sodium.

Bromfenac sodium Form I, characterized by an XRPD d-spacing/% intensity pattern in accordance with that shown in Table A and substantially free of any other physical forms of bromfenac sodium.

Bromfenac sodium Form I, characterized by an FT-IR spectrum in accordance with FIG. 2 and substantially free of any other physical forms of bromfenac sodium.

A pharmaceutical compound comprising bromfenac sodium Form I, characterized by a powder x-ray diffraction pattern having main peaks expressed as 2-theta at about 4.4, 8.8, 9.4, 12.1, 15.2, 15.9, 17.6, 18.2, 18.8, 20.2, 21.2, 24.7, 28.4, and 32.4 degrees, and wherein the compound does not contain more than 0.15% AUC of any process impurity or bromfenac sodium degradation product, as measured by HPLC.

A pharmaceutical compound comprising bromfenac sodium Form I, characterized by a powder x-ray diffraction pattern in accordance with that shown in FIG. 1, and wherein the compound does not contain more than 0.15% AUC of any process impurity or bromfenac sodium degradation product, as measured by HPLC.

A pharmaceutical compound comprising bromfenac sodium Form I, characterized by an XRPD d-spacing/% intensity pattern in accordance with that shown in Table A, and wherein the compound does not contain more than 0.15% AUC of any process impurity or bromfenac sodium degradation product, as measured by HPLC.

A pharmaceutical compound comprising bromfenac sodium Form I, characterized by an FT-IR spectrum in accordance with FIG. 2, and wherein the compound does not contain more than 0.15% AUC of any process impurity or bromfenac sodium degradation product, as measured by HPLC.